Crude and multivariable adjusted mixed effects modeling: prevalence ratio of BV and STIs during COVID-19 vs pre–COVID-19.a
| . | Prevalence ratio (95% CI) . | |
|---|---|---|
| . | Crude . | Adjusted . |
| BV | N=2738 | N=2544 |
| COVID-19 vs pre–COVID-19 | 2.00 (1.62-2.48) | 1.26 (1.00-1.59) b |
| STIs, c | N=1587 | N=1511 |
| COVID-19 vs pre–COVID-19 | 1.68 (1.40-2.02) | 1.36 (0.98-1.88) d |
| . | Prevalence ratio (95% CI) . | |
|---|---|---|
| . | Crude . | Adjusted . |
| BV | N=2738 | N=2544 |
| COVID-19 vs pre–COVID-19 | 2.00 (1.62-2.48) | 1.26 (1.00-1.59) b |
| STIs, c | N=1587 | N=1511 |
| COVID-19 vs pre–COVID-19 | 1.68 (1.40-2.02) | 1.36 (0.98-1.88) d |
Abbreviations: BV, bacterial vaginosis; PHQ-9, 9-item Personal Health Questionnaire; SES, socioeconomic status; STI, sexually transmitted infection; WASH, water, sanitation, and hygiene.
The pre–COVID-19 study visits of baseline through 18 months took place May 2018 through October 2019. Study visits at 30 through 48 months took place during the COVID-19 period, September 2020 through July 2022.
Simultaneously adjusted for the following: assigned intervention status; baseline WASH score, SES, sexual activity, and STI status; and time-varying age, SES, PHQ-9 score, engaging in transactional sex, and having a boyfriend.
Composite of testing positive for any of the following: Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis.
Simultaneously adjusted for the following: assigned intervention status; baseline WASH score, SES, and sexual activity; and time-varying age, SES, elevated PHQ-9 score, engaging in transactional sex, and having a boyfriend.
Crude and multivariable adjusted mixed effects modeling: prevalence ratio of BV and STIs during COVID-19 vs pre–COVID-19.a
| . | Prevalence ratio (95% CI) . | |
|---|---|---|
| . | Crude . | Adjusted . |
| BV | N=2738 | N=2544 |
| COVID-19 vs pre–COVID-19 | 2.00 (1.62-2.48) | 1.26 (1.00-1.59) b |
| STIs, c | N=1587 | N=1511 |
| COVID-19 vs pre–COVID-19 | 1.68 (1.40-2.02) | 1.36 (0.98-1.88) d |
| . | Prevalence ratio (95% CI) . | |
|---|---|---|
| . | Crude . | Adjusted . |
| BV | N=2738 | N=2544 |
| COVID-19 vs pre–COVID-19 | 2.00 (1.62-2.48) | 1.26 (1.00-1.59) b |
| STIs, c | N=1587 | N=1511 |
| COVID-19 vs pre–COVID-19 | 1.68 (1.40-2.02) | 1.36 (0.98-1.88) d |
Abbreviations: BV, bacterial vaginosis; PHQ-9, 9-item Personal Health Questionnaire; SES, socioeconomic status; STI, sexually transmitted infection; WASH, water, sanitation, and hygiene.
The pre–COVID-19 study visits of baseline through 18 months took place May 2018 through October 2019. Study visits at 30 through 48 months took place during the COVID-19 period, September 2020 through July 2022.
Simultaneously adjusted for the following: assigned intervention status; baseline WASH score, SES, sexual activity, and STI status; and time-varying age, SES, PHQ-9 score, engaging in transactional sex, and having a boyfriend.
Composite of testing positive for any of the following: Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis.
Simultaneously adjusted for the following: assigned intervention status; baseline WASH score, SES, and sexual activity; and time-varying age, SES, elevated PHQ-9 score, engaging in transactional sex, and having a boyfriend.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
